- US-listed companies
- Iterum Therapeutics plc
- Income statement
Iterum Therapeutics plc (ITRMF) Income statement
Market cap
$488K
P/E ratio
| 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 1 | 0 | - | - | - | - | - |
| Revenue growth (%) | - | - | - | - | - | - | |
| Research & development | 69 | 91 | 21 | 11 | 18 | 40 | 10 |
| Operating margin (%) | - | - | - | - | - | ||
| Operating expenses | 77 | 102 | 32 | 25 | 30 | 47 | 19 |
| Operating income | -77 | -102 | -32 | -25 | -30 | -47 | -19 |
| Income before tax | -77 | -103 | -51 | -91 | -44 | -38 | -25 |
| Pretax margin (%) | -8,812.9 | -277,529.7 | - | - | - | - | - |
| Provision for income taxes | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Effective tax rate (%) | |||||||
| Net income | -77 | -103 | -52 | -92 | -44 | -38 | -25 |
| Net income margin (%) | - | - | - | - | - | ||
| Earnings per share | - | - | - | - | -3.63 | -2.96 | -1.26 |
| Diluted EPS | - | - | - | - | -3.63 | -2.96 | -1.26 |